Enlivex Therapeutics (ENLV) has released an update.
Enlivex Therapeutics has reported promising results from its Phase II clinical trial of Allocetra™ in treating sepsis, showing significant reductions in organ failure scores and a 65% drop in mortality rates among patients, particularly those with high-risk urinary tract infections. Despite challenges in assessing Allocetra’s™ relative effect due to imbalances in patient severity at baseline, the treatment exhibited an acceptable safety profile. The company is considering further studies focused on high-risk urinary tract infection sepsis populations, addressing a substantial market need.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
